Successful Completion of MHRA Inspection (2657E)

TIDMABH

RNS Number : 2657E

Angel Biotechnology Holdings Plc

29 May 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Medicines and Healthcare products Regulatory Agency (MHRA) inspection

Angel Biotechnology Holdings plc, (AIM: ABH), the biopharmaceutical contract manufacturer, is pleased to announce that following the recent inspection by the MHRA at the Company's Pentlands facility, Angel has successfully retained both its Investigational Medicinal Products licence (IMP) and its Manufacturers' and Importers Authorisation licence (MIA). The inspector spent two full days at the Pentlands facility, had no critical or major observations to report and complemented the Company's staff on being well motivated and knowledgeable.

This news comes just shortly in advance of the inspection of Angel's Cramlington facility which is scheduled for the week commencing 11 June 2012.

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA).

Its customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has three facilities: Pentlands Science Park near Edinburgh where it employs 38 people, a site in Cramlington, near Newcastle-upon-Tyne, which is expected to employ up to 10 people by the end of 2012 and our new Angel Biomedical Ltd facility in Glasgow.

More information is available at www.angelbio.com .

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAKSPALKAEFF

Angel Biotechnology (LSE:ABH)
過去株価チャート
から 10 2024 まで 11 2024